# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0000950170-25-090404
**Filing Date:** 2025-6
**Character Count:** 14652
**Document Hash:** a158ebfd6e61665ff646736f0890e5fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-090404.hdr.sgml**: 20250626

**ACCESSION NUMBER**: 0000950170-25-090404

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250626

**DATE AS OF CHANGE**: 20250626

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94600
- **FILM NUMBER:** 251080534

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wildcat Capital Management, LLC
- **CENTRAL INDEX KEY:** 0001582384

**ORGANIZATION NAME:**
- **EIN:** 453715536
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1213

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 888 SEVENTH AVENUE
- **STREET 2:** 37TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10106
- **BUSINESS PHONE:** 212-468-5100

**MAIL ADDRESS:**
- **STREET 1:** 888 SEVENTH AVENUE
- **STREET 2:** 37TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10106

## Exhibit 99.3

**Exhibit 99.3**

Schedule A of the Schedule 13D is hereby amended in its entirety as follows:

**<u>Schedule A</u>**

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of Wildcat Capital Management, LLC:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Position and Present<br>Principal Occupation** | **Citizenship** | **Business Address** |
| Leonard A. Potter | Sole Member, President and Chief Investment Officer | United States | 888 Seventh Avenue, 37th Floor, New York, NY 10106 |
| Brian Rosenblatt | General Counsel, Chief Operating Officer and Chief Compliance Officer | United States | 888 Seventh Avenue, 37th Floor, New York, NY 10106 |

---

The following sets forth the name, position, address, principal occupation and citizenship of each general partner, control person, director and/or executive officer of Wildcat Partner Holdings, LP:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Position and Present<br>Principal Occupation** | **Citizenship** | **Business Address** |
| Samantha Holloway | <br>Position: President and Sole Member of Bond Management GP, LLC, the general partner of WPH<br>Present Principal Occupation: Chairperson, Seattle Kraken | United States | 10601 5th Ave NE, Suite 100 Seattle, WA 98125 |
| Sherri Conn | Position: Vice President of Bond Management GP, LLC, the general partner of WPH<br>Present Principal Occupation: Chief Financial Officer and Vice President of Tarrant Management, LLC | United States | 301 Commerce Street, Suite 3150, Fort Worth, TX 76102 |
| Tracy Ray | Position: Secretary of Bond Management GP, LLC, the general partner of WPH<br>Present Principal Occupation: Controller of Tarrant Management, LLC | United States | 301 Commerce Street, Suite 3150, Fort Worth, TX 76102 |

---

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Silexion Therapeutics Corp**

*(Name of Issuer)*

**Ordinary Shares, par value $0.0009 per share**

*(Title of Class of Securities)*

**G1281K122**

*(CUSIP Number)*

**Brian Rosenblatt**<br>888 Seventh Avenue<br>New York NY 10106<br>(212) 468-5100

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/26/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G1281K122** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Wildcat Capital Management, LLC** | Name of reporting person<br>**Wildcat Capital Management, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**113428.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**113428.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**113428.00** | Aggregate amount beneficially owned by each reporting person<br>**113428.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.3%** | Percent of class represented by amount in Row (11)<br>**1.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** Row 13. Based on 8,692,392 ordinary shares, par value $0.0009 per share, outstanding as of May 30, 2025, as reported by Silexion Therapeutics Corp in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025.

| **CUSIP No.** | **G1281K122** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Wildcat Partner Holdings, LP** | Name of reporting person<br>**Wildcat Partner Holdings, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**113428.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**113428.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**113428.00** | Aggregate amount beneficially owned by each reporting person<br>**113428.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.3%** | Percent of class represented by amount in Row (11)<br>**1.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Row 13. Based on 8,692,392 ordinary shares, par value $0.0009 per share, outstanding as of May 30, 2025, as reported by Silexion Therapeutics Corp in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025.

| **CUSIP No.** | **G1281K122** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Leonard A. Potter** | Name of reporting person<br>**Leonard A. Potter** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**113428.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**113428.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**113428.00** | Aggregate amount beneficially owned by each reporting person<br>**113428.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.3%** | Percent of class represented by amount in Row (11)<br>**1.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Row 13. Based on 8,692,392 ordinary shares, par value $0.0009 per share, outstanding as of May 30, 2025, as reported by Silexion Therapeutics Corp in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value $0.0009 per share

**(b) Name of Issuer:**
Silexion Therapeutics Corp

**(c) Address of Issuer's Principal Executive Offices:**
12 Abba Hillel Road, Ramat-Gan, L3, 5250606

EXPLANATORY NOTE

Except as set forth in this Amendment No. 1 (this "Amendment"), the initial Schedule 13D (the "Original 13D") that was filed on August 22, 2024, remains in effect, and capitalized terms used herein but not defined herein have such respective meanings, as defined in such Original 13D. The information set forth in response to the Item below shall be deemed to be a response to all Items where such information is relevant. The information set forth in the Exhibits to the Original 13D is expressly incorporated herein by reference and the response to each Item of this Statement is qualified in its entirety by the provisions of such Exhibits.

The Reporting Persons are filing this Amendment to reflect its new percentage beneficial ownership in the Issuer, which has decreased as a result of an increased in the number of shares of outstanding Ordinary Shares of the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Paragraphs (a), (b) and (e) of Item 5 of the Original 13D are hereby amended and restated in their entirety as follows:

The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Statement is incorporated by reference in its entirety into this Item 5.

(a), (b) The percentage of Ordinary Shares beneficially owned by the Reporting Persons is based 8,692,392 Ordinary Shares outstanding as of May 30, 2025, as reported by the Issuer in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 16, 2025. Each of the Reporting Persons has the power to vote and dispose of the Ordinary Shares beneficially owned by such entity (as described above), and each of the Reporting Persons expressly disclaims beneficial ownership of any Ordinary Shares not owned directly by it except to the extent of any pecuniary interest therein. Wildcat Capital, as the investment manager of the WPH, has the authority to vote and dispose of all of the Ordinary Shares reported in this Schedule 13D, but expressly disclaims beneficial ownership of any Ordinary Shares not owned directly by it except to the extent of its pecuniary interest therein.

Each Reporting Person expressly disclaims beneficial ownership of any securities reported herein except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities and except to the extent of such Reporting Person's pecuniary interest therein.

**(b)**
See item 5(a).

**(c)**
—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Wildcat Capital Management, LLC

**Signature:** /s/Leonard A. Potter

**Name/Title:** Leonard A. Potter/President

**Date:** 06/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Wildcat Partner Holdings, LP

**Signature:** /s/Sherri Conn

**Name/Title:** Sherri Conn/Vice President

**Date:** 06/26/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Leonard A. Potter

**Signature:** /s/Leonard A. Potter

**Name/Title:** Leonard A. Potter

**Date:** 06/26/2025